- Home
- MDB vs ILMN Comparison
MDB vs ILMN Comparison
Compare MDB & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDB
- ILMN
- Stock Information
- Founded
- MDB 2007
- ILMN 1998
- Country
- MDB United States
- ILMN United States
- Employees
- MDB N/A
- ILMN N/A
- Industry
- MDB Computer Software: Prepackaged Software
- ILMN Medical Specialities
- Sector
- MDB Technology
- ILMN Health Care
- Exchange
- MDB Nasdaq
- ILMN Nasdaq
- Market Cap
- MDB 15.6B
- ILMN 15.9B
- IPO Year
- MDB 2017
- ILMN 2000
- Fundamental
- Price
- MDB $159.26
- ILMN $71.20
- Analyst Decision
- MDB Buy
- ILMN Buy
- Analyst Count
- MDB 31
- ILMN 18
- Target Price
- MDB $308.42
- ILMN $139.50
- AVG Volume (30 Days)
- MDB 2.4M
- ILMN 2.6M
- Earning Date
- MDB 05-29-2025
- ILMN 05-08-2025
- Dividend Yield
- MDB N/A
- ILMN N/A
- EPS Growth
- MDB N/A
- ILMN N/A
- EPS
- MDB N/A
- ILMN N/A
- Revenue
- MDB $2,006,443,000.00
- ILMN $4,372,000,000.00
- Revenue This Year
- MDB $14.53
- ILMN $0.09
- Revenue Next Year
- MDB $16.71
- ILMN $4.71
- P/E Ratio
- MDB N/A
- ILMN N/A
- Revenue Growth
- MDB 19.22
- ILMN N/A
- 52 Week Low
- MDB $140.78
- ILMN $68.70
- 52 Week High
- MDB $387.19
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- MDB 37.08
- ILMN 34.18
- Support Level
- MDB $155.41
- ILMN $68.70
- Resistance Level
- MDB $168.64
- ILMN $76.16
- Average True Range (ATR)
- MDB 10.91
- ILMN 4.18
- MACD
- MDB 2.10
- ILMN 0.38
- Stochastic Oscillator
- MDB 43.77
- ILMN 17.78
About MDB MongoDB Inc.
Founded in 2007, MongoDB is a document-oriented database. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.